HC Wainwright Weighs in on Skye Bioscience Q3 Earnings

Skye Bioscience, Inc. (NASDAQ:SKYE) – Investment analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Skye Bioscience in a research note issued to investors on Tuesday, September 30th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Skye Bioscience’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Skye Bioscience’s Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($2.04) EPS and FY2029 earnings at ($2.47) EPS.

Skye Bioscience (NASDAQ:SKYE) last announced its earnings results on Thursday, August 7th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.10).

Several other analysts also recently weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $15.00 target price on shares of Skye Bioscience in a report on Tuesday, June 24th. Evercore ISI raised Skye Bioscience to a “strong-buy” rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, Skye Bioscience presently has an average rating of “Buy” and an average target price of $14.75.

Skye Bioscience Stock Performance

Skye Bioscience stock opened at $4.49 on Thursday. The company’s 50 day simple moving average is $3.71 and its 200-day simple moving average is $2.99. Skye Bioscience has a 1 year low of $1.14 and a 1 year high of $5.96. The company has a market capitalization of $139.14 million, a price-to-earnings ratio of -4.24 and a beta of 2.34.

Institutional Trading of Skye Bioscience

Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP purchased a new stake in Skye Bioscience during the 4th quarter worth about $32,000. Capital Advisors Wealth Management LLC acquired a new stake in shares of Skye Bioscience during the 1st quarter worth about $33,000. Nuveen LLC purchased a new stake in Skye Bioscience during the first quarter worth approximately $37,000. Squarepoint Ops LLC acquired a new position in Skye Bioscience in the fourth quarter valued at approximately $38,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Skye Bioscience in the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 21.09% of the company’s stock.

Insider Buying and Selling at Skye Bioscience

In related news, major shareholder 5Am Partners Vii, Llc sold 170,449 shares of Skye Bioscience stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $3.42, for a total value of $582,935.58. Following the completion of the transaction, the insider directly owned 57,493 shares in the company, valued at approximately $196,626.06. This trade represents a 74.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Andrew J. Schwab sold 170,449 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $3.42, for a total value of $582,935.58. Following the transaction, the director directly owned 57,493 shares of the company’s stock, valued at $196,626.06. The trade was a 74.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 462,810 shares of company stock worth $1,601,097. Insiders own 4.50% of the company’s stock.

About Skye Bioscience

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.